keyword
https://read.qxmd.com/read/38641745/endothelial-deubiquinatase-yod1-mediates-ang-ii-induced-vascular-endothelial-mesenchymal-transition-and-remodeling-by-regulating-%C3%AE-catenin
#21
JOURNAL ARTICLE
Wan-Te Lin, Yu-Cheng Jiang, Yi-Lin Mei, Yang-Hao Chen, Zhao-Zheng Zheng, Xue Han, Gao-Jun Wu, Wei-Jian Huang, Bo-Zhi Ye, Guang Liang
Hypertension is a prominent contributor to vascular injury. Deubiquinatase has been implicated in the regulation of hypertension-induced vascular injury. In the present study we investigated the specific role of deubiquinatase YOD1 in hypertension-induced vascular injury. Vascular endothelial endothelial-mesenchymal transition (EndMT) was induced in male WT and YOD1-/- mice by administration of Ang II (1 μg/kg per minute) via osmotic pump for four weeks. We showed a significantly increased expression of YOD1 in mouse vascular endothelial cells upon Ang II stimulation...
April 19, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38640784/implantable-car-t-cell-factories-enhance-solid-tumor-treatment
#22
JOURNAL ARTICLE
Sharda Pandit, Pritha Agarwalla, Feifei Song, Anton Jansson, Gianpietro Dotti, Yevgeny Brudno
Chimeric Antigen Receptor (CAR) T cell therapy has produced revolutionary success in hematological cancers such as leukemia and lymphoma. Nonetheless, its translation to solid tumors faces challenges due to manufacturing complexities, short-lived in vivo persistence, and transient therapeutic impact. We introduce 'Drydux' - an innovative macroporous biomaterial scaffold designed for rapid, efficient in-situ generation of tumor-specific CAR T cells. Drydux expedites CAR T cell preparation with a mere three-day turnaround from patient blood collection, presenting a cost-effective, streamlined alternative to conventional methodologies...
April 15, 2024: Biomaterials
https://read.qxmd.com/read/38640773/secondary-cytoreductive-surgery-and-oncologic-outcomes-in-the-era-of-targeted-maintenance-therapy-for-recurrent-platinum-sensitive-ovarian-cancer
#23
JOURNAL ARTICLE
Sarah Ehmann, Clarissa Lam, Qin Zhou, Alexia Iasonos, Rachel N Grisham, William P Tew, Roisin E O'Cearbhaill, Kara Long Roche, Oliver Zivanovic, Yukio Sonoda, Dennis S Chi, Ginger J Gardner
OBJECTIVES: To compare oncologic outcomes of secondary cytoreductive surgery (SCS) before and after FDA approval of Poly(ADP-ribose) polymerase inhibitor (PARPi) and bevacizumab maintenance therapies for platinum-sensitive recurrent ovarian cancer (PS-ROC). METHODS: Patients who underwent SCS for first recurrence of PS-ROC from 1/1/2013-1/1/2020 were identified. Exclusion criteria included prior chemotherapy for recurrence, bowel obstruction procedures, and palliative surgery...
April 18, 2024: Gynecologic Oncology
https://read.qxmd.com/read/38640714/prospects-and-challenges-of-car-t-in-the-treatment-of-ovarian-cancer
#24
REVIEW
Biqing Chen, Jiaqi Liu
Ovarian cancer ranks as the seventh most prevalent cancer among women and is considered the most lethal gynecological malignancy on a global scale. The absence of reliable screening techniques, coupled with the insidious onset of nonspecific symptoms, often results in a delayed diagnosis, typically at an advanced stage characterized by peritoneal involvement. Management of advanced tumors typically involves a combination of chemotherapy and cytoreductive surgery. However, the therapeutic arsenal for ovarian cancer patients remains limited, highlighting the unmet need for precise, targeted, and sustained-release pharmacological agents...
April 18, 2024: International Immunopharmacology
https://read.qxmd.com/read/38640321/machine-learning-developed-a-fibroblast-related-signature-for-predicting-clinical-outcome-and-drug-sensitivity-in-ovarian-cancer
#25
JOURNAL ARTICLE
Wei Fu, Qian Feng, Ran Tao
Ovarian cancer (OC) is the leading cause of gynecological cancer death. Cancer-associated fibroblasts (CAF) is involved in wound healing and inflammatory processes, tumor occurrence and progression, and chemotherapy resistance in OC. GSE184880 dataset was used to identify CAF-related genes in OC. CAF-related signature (CRS) was constructed using integrative 10 machine learning methods with the datasets from the Cancer Genome Atlas, GSE14764, GSE26193, GSE26712, GSE63885, and GSE140082. The performance of CRS in predicting immunotherapy benefits was verified using 3 immunotherapy datasets (GSE91061, GSE78220, and IMvigor210) and several immune calculating scores...
April 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38639401/fetpy-a-diiron-i-thio-carbyne-complex-with-prominent-anticancer-activity-in-vitro-and-in-vivo
#26
JOURNAL ARTICLE
Ekatarina Mihajlović, Lorenzo Biancalana, Sanja Jelača, Lorenzo Chiaverini, Biljana Dojčinović, Duško Dunđerović, Stefano Zacchini, Sanja Mijatović, Danijela Maksimović-Ivanić, Fabio Marchetti
FETPY , an organo-diiron(I) complex, showed strong cytotoxicity across a panel of human and mouse cancer cell lines, combined with an outstanding selectivity compared to nonmalignant cells. Enhanced iron uptake in aggressive, low-differentiated cell lines, caused membrane lipid peroxidation, which resulted in ferroptosis in human ovarian cancer cells. FETPY induced significant morphological changes in murine B16-F1 and B16-F10 melanoma cells, leading to senescence and/or trans-differentiation into Schwann-like cells, thus significantly reducing their tumorigenic potential...
April 19, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38639279/cldn18-clinical-pathological-and-genetic-signatures-with-drug-screening-in-gastric-adenocarcinoma
#27
JOURNAL ARTICLE
Joon Young Hur, Kyueng-Whan Min, Yung-Kyun Noh, Young-Woong Won, Yoomi Yeo, Dong-Hoon Kim, Byoung Kwan Son, Mi Jung Kwon, Jung Soo Pyo
INTRODUCTION: The CLDN18 gene, encoding claudin 18.1 and claudin 18.2, is a key component of tight junction strands in epithelial cells that form a paracellular barrier that is critical in Stomach Adenocarcinoma (STAD). METHODS: Our study included 1,095 patients with proven STAD, 415 from The Cancer Genome Atlas (TCGA) cohort and 680 from the Gene Expression Omnibus database. We applied various analyses, including gene set enrichment analysis, pathway analysis, and in vitro drug screening to evaluate survival, immune cells, and genes and gene sets associated with cancer progression, based on CLDN18 expression levels...
April 18, 2024: Current Medicinal Chemistry
https://read.qxmd.com/read/38639044/genomic-catastrophe-chromothripsis-and-polyploidy-correlates-with-tumor-distribution-in-extrauterine-high-grade-serous-carcinoma
#28
JOURNAL ARTICLE
Ju-Yoon Yoon, Aarti Sharma, Azra H Ligon, Rebecca G Ramesh, T Rinda Soong, Wa Xian, David B Chapel, Christopher P Crum
Most extrauterine high-grade serous carcinomas (HGSCs) are thought to develop first in the distal fallopian tube. Most models of HGSC assume origin from relatively stable, noninvasive serous tubal intraepithelial carcinomas. However, widespread tumor involvement in the absence of a serous tubal intraepithelial carcinoma could occur after catastrophic genomic events (CGEs; such as chromothripsis or polyploidy). Twenty-six HGSCs assigned to fallopian tube (n = 9, group 1) and/or ovary (n = 9, group 2), and primary peritoneal (n = 8, group 3) were assessed by microarray (Oncoscan)...
April 18, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38638796/matrix-metalloproteinase-7-promoter-site-single-nucleotide-polymorphism-181a-g-in-epithelial-ovarian-cancer-in-the-eastern-indian-population
#29
JOURNAL ARTICLE
Anudeep P P, Suchitra Kumari, Saroj Dasmajumdar, Manaswini Mangaraj
BACKGROUND: Matrix metalloproteinase-7 (MMP7) plays multiple roles in different stages of tumor development. Elevated MMP7 activity has been reported in ovarian cancer. Single nucleotide polymorphism (SNP) of promoter sites of the MMP7 gene has been shown to cause alteration in gene expression, hence resulting in changes in susceptibility to various diseases and tumor development. METHODS: The current study evaluated the association of epithelial ovarian cancer risk with MMP7 promoter site -181A>G polymorphism in the population of eastern India...
March 2024: Curēus
https://read.qxmd.com/read/38637885/mesothelin-based-car-t-cells-exhibit-potent-antitumor-activity-against-ovarian-cancer
#30
JOURNAL ARTICLE
Jing Guo, Xiaozhu Zeng, Yongjie Zhu, Dong Yang, Xudong Zhao
BACKGROUND: Ovarian cancer (OC) is characterized by its rapid growth and spread which, accompanied by a low 5-year survival rate, necessitates the development of improved treatments. In ovarian cancer, the selective overexpression of Mucin-16 (MUC16, CA125) in tumor cells highlights its potential as a promising target for developing anti-tumor therapies. However, the potential effectiveness of CAR-T cell therapy that targets MUC16 in ovarian cancer cells is unknown. METHODS: The expression of MUC16 in viable OC cells was detected using immunofluorescence and flow cytometry techniques...
April 18, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38637813/alkbh5-modulates-macrophages-polarization-in-tumor-microenvironment-of-ovarian-cancer
#31
JOURNAL ARTICLE
Yuanyuan An, Hua Duan
BACKGROUND: Macrophages play an essential role in regulating ovarian cancer immune microenvironment. Studies have shown that m6A methylation could influence immune microenvironment in cancer. In this study, we investigated the roles of m6A demethylase ALKBH5 and m6A recognition protein IGF2BP2 played in regulating macrophages polarization in ovarian cancer. METHODS: In this study, we first explored the differentially expressed m6A methylation enzymes in M0 and M2 macrophages according to two independent GEO datasets...
April 18, 2024: Journal of Ovarian Research
https://read.qxmd.com/read/38637800/primary-lymphoma-of-the-female-genital-tract-masquerading-as-gynecological-malignancy
#32
JOURNAL ARTICLE
Suhua Shi, Wuan Li, Guantai Ni, Jin Ding, Yinhua Liu, Haixing Wu, Zhen Zhang, Zhimin Ding
BACKGROUND: Primary lymphoma of the female genital tract (PLFGT) is a rare malignant tumor in the female reproductive system, with a low incidence and few clinical reports. The aim of this study is to report our institutional experience with this rare malignancy and emphasize the need for increasing the awareness about PLFGT presenting with gynecologic symptoms. METHODS: The medical records of patients diagnosed with PLFGT from March 2014 to November 2022 in the First Affiliated Hospital of Wannan Medical College were reviewed...
April 18, 2024: BMC Women's Health
https://read.qxmd.com/read/38636338/syk-dependent-homologous-recombination-activation-promotes-cancer-resistance-to-dna-targeted-therapy
#33
JOURNAL ARTICLE
Qin Zhou, Xinyi Tu, Xiaonan Hou, Jia Yu, Fei Zhao, Jinzhou Huang, Jake Kloeber, Anna Olson, Ming Gao, Kuntian Luo, Shouhai Zhu, Zheming Wu, Yong Zhang, Chenyu Sun, Xiangyu Zeng, Kenneth J Schoolmeester, John S Weroha, Xiwen Hu, Yanxia Jiang, Liewei Wang, Robert W Mutter, Zhenkun Lou
Enhanced DNA repair is an important mechanism of inherent and acquired resistance to DNA targeted therapies, including poly ADP ribose polymerase (PARP) inhibition. Spleen associated tyrosine kinase (Syk) is a non-receptor tyrosine kinase acknowledged for its regulatory roles in immune cell function, cell adhesion, and vascular development. This study presents evidence indicating that Syk expression in high-grade serous ovarian cancer and triple-negative breast cancers promotes DNA double-strand break resection, homologous recombination (HR), and subsequent therapeutic resistance...
April 16, 2024: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/38636303/neil-1-deficiency-facilitates-chemoresistance-through-upregulation-of-rad18-expression-in-ovarian-cancer-stem-cells
#34
JOURNAL ARTICLE
Devendra Shukla, Tanima Mandal, Amit Kumar Srivastava
Over the past decades, cancer stem cells (CSCs) have emerged as a critical subset of tumor cells associated with tumor recurrence and resistance to chemotherapy. Understanding the mechanisms underlying CSC-mediated chemoresistance is imperative for improving cancer therapy outcomes. This study delves into the regulatory role of NEIL1, a DNA glycosylase, in chemoresistance in ovarian CSCs. We first observed a decreased expression of NEIL1 in ovarian CSCs, suggesting its potential involvement in CSC regulation...
April 12, 2024: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/38635934/randomized-phase-ii-study-of-gemcitabine-with-or-without-atr-inhibitor-berzosertib-in-platinum-resistant-ovarian-cancer-final-overall-survival-and-biomarker-analyses
#35
JOURNAL ARTICLE
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Andrea E Wahner Hendrickson, Bose Kochupurakkal, David L Kolin, Elise C Kohn, Joyce F Liu, Richard T Penson, Elizabeth H Stover, Jennifer Curtis, Hannah Sawyer, Madeline Polak, Dipanjan Chowdhury, Alan D D'Andrea, Anniina Färkkilä, Geoffrey I Shapiro, Ursula A Matulonis
PURPOSE: The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (hazard ratio [HR]=0.57, one-sided log-rank P = .044, which met the one-sided significance level of 0.1 used for sample size calculation). METHODS: We report here the final overall survival (OS) analysis and biomarker correlations (ATM expression by immunohistochemistry, mutational signature 3 and a genomic biomarker of replication stress) along with post-hoc exploratory analyses to adjust for crossover from gemcitabine to gemcitabine/berzosertib...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38635893/ovarian-serous-carcinoma-with-stomach-metastasis-a-rare-case-report-and-literature-review
#36
JOURNAL ARTICLE
Jia-Li Hu, Zhao-Jiao Guo, Chun Wang, Jun Yan, Hao Yang
Ovarian cancer is a common tumor among women. It is often asymptomatic in the early stages, with most cases already at stage III to IVE at the time of diagnosis. Direct spread and lymphatic metastasis are the primary modes of metastasis, whereas hematogenous spread is rare. An initial diagnosis of ovarian cancer that has metastasized to the stomach is also uncommon. Therefore, clear treatment methods and prognostic data for such metastasis are lacking. In our hospital, we encountered a patient with an initial imaging diagnosis of a gastric tumor and a history of an ovarian tumor with endoscopic abdominal metastasis...
April 2024: Journal of International Medical Research
https://read.qxmd.com/read/38635891/omental-preadipocytes-stimulate-matrix-remodeling-and-igf-signaling-to-support-ovarian-cancer-metastasis
#37
JOURNAL ARTICLE
Jennifer A Waters, Mikella Robinson, Omar Lujano-Olazaba, Cassidy Lucht, Samuel F Gilbert, Carrie D House
Ovarian cancer can metastasize to the omentum, which is associated with a complex tumor microenvironment. Omental stromal cells facilitate ovarian cancer colonization by secreting cytokines and growth factors. Improved understanding of the tumor supportive functions of specific cell populations in the omentum could identify strategies to prevent and treat ovarian cancer metastasis. Here, we showed that omental preadipocytes enhance the tumor initiation capacity of ovarian cancer cells. Secreted factors from preadipocytes supported cancer cell viability during nutrient and isolation stress and enabled prolonged proliferation...
April 18, 2024: Cancer Research
https://read.qxmd.com/read/38634567/tau-aggregation-dependent-lipid-peroxide-accumulation-driven-by-the-hsa_circ_0001546-14-3-3-camk2d-tau-complex-inhibits-epithelial-ovarian-cancer-peritoneal-metastasis
#38
JOURNAL ARTICLE
BinShu Chai, Yong Wu, HengHui Yang, BiaoFeng Fan, SiYu Cao, XiaoFei Zhang, YaQing Xie, ZhiXiang Hu, ZhongLiang Ma, YunKui Zhang, Wei Pan, Wei Meng, Jiao Meng, WenJuan Tian, JiaLi Zhang, YanLi Li, Yang Shao, ShaoJia Wang
Intraperitoneal dissemination is the main method of epithelial ovarian cancer (EOC) metastasis, which is related to poor prognosis and a high recurrence rate. Circular RNAs (circRNAs) are a novel class of endogenous RNAs with covalently closed loop structures that are implicated in the regulation of tumor development. In this study, hsa_circ_0001546 is downregulated in EOC primary and metastatic tissues vs. control tissues and this phenotype has a favorable effect on EOC OS and DFS. hsa_circ_0001546 can directly bind with 14-3-3 proteins to act as a chaperone molecule and has a limited positive effect on 14-3-3 protein stability...
April 18, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38634058/vista-ctla4-pd1-coexpression-on-tumor-cells-confers-a-favorable-immune-microenvironment-and-better-prognosis-in-high-grade-serous-ovarian-carcinoma
#39
JOURNAL ARTICLE
Aida Jlassi, Rim Rejaibi, Maroua Manai, Ghada Sahraoui, Fatma Zahra Guerfali, Lamia Charfi, Amel Mezlini, Mohamed Manai, Karima Mrad, Raoudha Doghri
INTRODUCTION: Immunotherapy by blocking immune checkpoints programmed death/ligand (PD1/PDL1) and cytotoxic T-lymphocyte-associated protein 4(CTLA4) has emerged as new therapeutic targets in cancer. However, their efficacy has been limited due to resistance. A new- checkpoint V-domain Ig-containing suppressor of T cell activation (VISTA) has appeared, but the use of its inhibition effect in combination with antibodies targeting PDL1/PD1and CTLA4 has not been reported in ovarian cancer...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38633673/pembrolizumab-with-bevacizumab-and-cyclophosphamide-for-the-treatment-of-recurrent-ovarian-clear-cell-carcinoma-a-case-series
#40
Shannon M Glynn, Stephanie Gaillard, Rebecca L Stone, Amanda N Fader, Anna L Beavis
INTRODUCTION: Treatment for recurrent ovarian clear cell carcinoma (OCCC) is clinically challenging as response rates to traditional chemotherapy are low, and recurrence rates are high. Immunotherapy has shown promise for this ovarian cancer (OC) subtype, and tumor molecular testing allows for the identification of a patient population that might benefit most from this treatment. We describe the clinical course and somatic genomic testing of 4 patients who received pembrolizumab for recurrent OCCC concurrent with a combination of bevacizumab and/or cyclophosphamide...
June 2024: Gynecologic Oncology Reports
keyword
keyword
46046
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.